Adding Aimovig to Botox for Migraine Prevention
Yes, adding Aimovig (erenumab) to Botox (onabotulinumtoxinA) is justified in patients with chronic migraine who remain inadequately controlled on Botox alone. This combination represents an evidence-based escalation strategy for refractory chronic migraine.
Clinical Rationale
The combination of these two preventive therapies targets different mechanisms in migraine pathophysiology:
- Botox (onabotulinumtoxinA) prevents CGRP release from peripheral unmyelinated C-fibers and extracranial nerve terminals
- Aimovig (erenumab) blocks the canonical CGRP receptor on myelinated Aδ-fibers
This dual mechanism provides complementary therapeutic coverage of the CGRP pathway 1.
Evidence Supporting Combination Therapy
Guideline Framework
Current guidelines establish the treatment hierarchy for chronic migraine. Evidence-based preventive options for chronic migraine include topiramate, onabotulinumtoxinA, and CGRP monoclonal antibodies 2. Regulatory restrictions typically limit CGRP antibodies to patients who have failed 2-3 other preventive medications 2.
The 2021 Nature Reviews Neurology guideline positions both therapies as third-line options, with CGRP antibodies (including erenumab) proven beneficial in patients who have failed at least two other preventive medications 2.
Real-World Combination Data
Multiple retrospective studies demonstrate efficacy of adding erenumab to ongoing Botox therapy:
Most compelling evidence: A 2022 retrospective cohort (n=50) showed that adding erenumab to onabotulinumtoxinA significantly reduced monthly migraine days (11.3 vs 14.9 days, p<0.001) and monthly headache days (18.2 vs 20.7 days, p=0.042) compared to Botox alone, with no severe adverse effects 3.
A larger 2021 retrospective study (n=78) demonstrated significant reductions in both monthly headache days and monthly migraine days at 30,60, and 90 days after adding erenumab to patients still suffering on Botox therapy (reductions of -8.1 headache days and -7.4 migraine days at 90 days, both p<0.001) 1.
Real-world safety data: A 2021 chart review of 257 patients receiving combination therapy found it well-tolerated with no new safety signals. Mean headache frequency decreased from 21.5 days before Botox to 12.1 days on Botox alone, then further decreased by 3.5-4.0 days over 6-12 months of combination treatment. Adverse events occurred in 28% of patients, most commonly constipation (9%) 4.
Contradictory Evidence
Important caveat: One 2023 retrospective study (n=187) suggested dual therapy may be less effective than erenumab alone, with smaller reductions in monthly headache days (4.7 days with combination vs 8.21 days with erenumab alone, p=0.009) 5. However, the authors acknowledged multiple study limitations and called for prospective validation.
Clinical Decision Algorithm
Proceed with adding Aimovig if:
- Patient has chronic migraine (≥15 headache days/month)
- Currently receiving regular Botox injections (155-195 units every 12 weeks)
- Inadequate response to Botox alone (still experiencing significant disability)
- Has failed at least 2-3 other preventive medication classes
- No contraindications to erenumab (see safety considerations below)
Dosing: Start with erenumab 70 mg subcutaneously monthly; may increase to 140 mg monthly if inadequate response after 3 months 6.
Continue Botox: Maintain the current Botox regimen while adding erenumab 3, 1, 4.
Safety Considerations
Monitor for erenumab-specific adverse effects 6:
- Constipation (most common, up to 13%): Can be severe requiring hospitalization. Monitor closely, especially with concurrent medications that decrease GI motility
- Hypertension: New-onset or worsening hypertension, typically within 7 days of first dose. Monitor blood pressure regularly
- Hypersensitivity reactions: Rash, angioedema, anaphylaxis (rare but serious). Discontinue if severe reaction occurs
- Injection site reactions: Pain, erythema, pruritus (6% incidence)
Contraindications: Hypersensitivity to erenumab 6.
Expected Timeline and Outcomes
- Initial assessment: Evaluate response at 3 months
- Sustained benefit: Efficacy typically increases over 6-12 months of combination therapy 4
- Realistic expectations: Additional 3.5-8 day reduction in monthly headache days beyond Botox alone 3, 1, 4
- Responder rates: 45-76% achieve ≥50% reduction in monthly migraine days 3, 1
Common Pitfalls
Medication overuse headache: Before adding erenumab, ensure the patient is not overusing acute medications (≥10 days/month for triptans, ≥15 days/month for NSAIDs) 7. Address medication overuse first, as this can confound treatment response.
Premature discontinuation: Allow adequate trial duration (at least 3-6 months) before declaring treatment failure, as efficacy often increases over time 4.
Insurance authorization: Document prior treatment failures and ongoing disability to support medical necessity for combination therapy, as this represents off-label use of two expensive preventive therapies.